This interesting article proposes dividing patients non-responsible to GLP-1 drugs into three different categories

[keangkong]

Fajkić, et al. (2025). Decoding incretin resistance - a mechanistic framework to reclassify therapeutic variability for GLP-1 receptor agonist therapy. Amino Acids 57, 55.